NORVIR
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
NORVIR by Abbott is [see microbiology ( ) ] . Approved for combination with other antiretroviral agents for the treatment of pediatric patients with hiv-1 infection. First approved in 1996.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral protease inhibitor approved in 1996 for combination antiretroviral therapy in pediatric patients with HIV-1 infection. It works by inhibiting HIV protease, preventing viral replication and disease progression. NORVIR is predominantly used as a pharmacokinetic booster in modern regimens rather than as primary therapy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating shrinking commercial team and shift toward lifecycle extension or transition activities.
Mechanism of Action
[see Microbiology ( ) ] .
Clinical Trials (1)
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada
Started Jan 2008
35 enrolled
HIV Infections
Career Relevance
NORVIR represents a career challenge rather than opportunity: zero linked job openings reflect LOE-stage maturity and declining investment. Professionals on this team are likely focused on cost management, generic transition planning, or organizational restructuring rather than growth initiatives.
Worked on NORVIR at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.